Alexion Pharmaceuticals, which specialises in treatments for severe and rare disorders, has confirmed plans to create 200 jobs in Ireland.
The jobs creation will take place over the next four years as part of the biopharmaceutical firm’s expansion project at its College Park site in Blanchardstown, Dublin.
Welcoming the announcement, Tanaiste Joan Burton said it demonstrated that a jobs-led recovery is “now under way”.
“Alexion’s latest expansion is an extremely strong endorsement for Ireland, and Dublin West in particular, as an attractive location for high-end investment from the pharmaceutical industry,” she said.
Alexion has invested 130m euros in two other facilities since setting up in Ireland back in 2013.
The biopharmaceutical firm’s College Park facility will become the first biologics manufacturing facility outside the United States to use human genes in the creation of proteins.
Once construction finishes at the site, Alexion’s workforce is expected to rise to around 500.
Alexion, biopharmaceuticals, Pharmaceuticals,
An in and outside the (bioprocess) box thinker, fluid management specialist Phill knows a thing or two about keeping pharma liquid logistics flowing.